CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients
- CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress

LISBON, Portugal 15 June 2018 Global biotherapeutics leader CSL Behring today announced that it will participate in the 4th Congress of the European Academy of Neurology (EAN) in Lisbon, Portugal 2018. CSL Behring will support one oral presentation and four ePresentation sessions and host a booth (A14) where attendees will have the opportunity to partner with CSL Behring as the Company donates to the GBS|CIDP Foundation International for every badge scanned at their booth, up to 15,000 euros.

“CSL Behring is excited to participate in this year’s EAN Congress,” said Lutz Bonacker, Senior Vice President Commercial Operations Europe, CSL Behring. “Our presence at this congress allows us to continue to learn and share discoveries within this community, and underscores our continued commitment to develop therapies that treat rare neurological conditions in support of our patients and our physicians.”

An oral session, Axonal Function Predicts Response to Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study will be featured on Saturday, 16 June from 16:45 to 18:00 and will be presented by Dr. Vera Bril, Department of Medicine (Neurology), University Health Network, University of Toronto, Toronto General Hospital, Canada.

Four presentations summarizing research supported by CSL Behring will be available as ePresentations during the meeting, including:

  • Benefit-Risk Profile of Intravenous Immunoglobulin (IVIg) and Subcutaneous Immunoglobulin (SCIg) in CIDP: the PATH study, Amgad Shebl et al: Presentation #EPR1164 on Screen B12 on Saturday, 16 June from 13:30 to 14:15
  • Feasibility of Switching from IVIg to SCIg Therapy in CIDP: Comparison of PATH Trial Results with Clinical Experience, Dario Cocito et al: Presentation #EPR1172 on Screen B12 on Saturday, 16 June from 13:30 to 14:15
  • Efficacy and Safety of Intravenous Immunoglobulin (IVIg) IgPro10 in CIDP: Combined Analysis of the PRIMA and PATH Studies, Ingemar S.J. Merkies et al: Presentation #EPR2157 on Screen B4 on Sunday, 17 June from 13:30 to 14:15
  • Restabilisation Treatment After IVIg Withdrawal in CIDP: Results from the PATH study, Orell Mielke et al: Presentation #EPR2156 on Screen B4 on Sunday, 17 June from 13:30 to 14:15

CSL Behring has a long history in delivering on its promise to develop immunoglobulin therapies to treat rare conditions related to the immune and neurologic systems. CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, approved for treating CIDP since 2013. 

About CIDP

In CIDP, a rare autoimmune disorder that affects the peripheral nerves (those outside the brain and spinal cord), the myelin sheath, the protective covering of the nerves, is damaged. This may result in numbness or tingling, muscle weakness, fatigue, and other symptoms. CIDP effects can worsen over time, leading to significant activity limitations and a decreased quality of life. CIDP can occur at any age and is more common in men than in women. Approximately 30 percent of CIDP patients will progress to wheelchair dependence if not treated. It is estimated that the global incidence of CIDP is 0.5 to 1.6 patients per 100,000 individuals each year, with a prevalence of 1.0 to 8.9 per 100,000 people.

About Hizentra®

Hizentra (human normal immunoglobulin, SCIg), the first 20 percent subcutaneous immunoglobulin developed for subcutaneous use, is registered in over 51 countries and approved to treat CIDP and certain immune deficiencies. Hizentra, the world's most prescribed subcutaneous immunoglobulin, has a proven track record of safety, efficacy, and tolerability and has over 4.8 million exposures worldwide since 2010.

 

About Privigen®

Privigen (human normal immunoglobulin, IVIg), is the first and only 10 percent, ready to use, room-temperature stored, liquid IVIg stabilized with proline. A naturally occurring amino acid, proline has been shown to reduce IgG aggregation and dimer formation. Privigen has been approved to treat CIDP since 2013. Privigen is also approved for treating certain immune deficiencies, primary immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, and Kawasaki disease. It is approved in 80 countries around the world for treating these and other rare diseases.

 

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, delivering its life-saving therapies to people in more than 60 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

# # #

Media Contact
Jennifer Purdue
Office: +1 610 878 4802
Mobile: +1 610 306 9355
Email:
jennifer.purdue@cslbehring.com